HEALTHCARE AND LIFE SCIENCES
IT stocks: A comeback which just needs a bit more confirmation; 7 stocks with an upside potential of up to 23%
Just before the expiry of the June series contract, bulls were seen in a segment of the market which has been long ignored by them — IT stocks. Because the upward movement was taking place at the end of expiry, one could not rule out the element of short covering. If one looks a bit deeper in the trend in IT stocks, two things have become clear. That while the news and opinion has been negative, the price action has not been so bad as has been painted. Now let's look at what happened in the IT sector and why there could be a case for contrarian buying. Yes, the sector has some headwinds which not many had thought would appear two years back. But the bigger question is whether this phase of underperformance is about to get over or not. It might be time to shed the bias of negativity around large IT players.
Everstone to merge two healthcare companies, list combined firm
Everstone Capital, a Pan Asia private equity fund, is merging Translumina Therapeutics, a major cardiac stent maker in India, as part of a big-ticket IPO plan.
Companies cautious on short-term hiring, but overall outlook stays upbeat
Employers in India are showing caution in short-term hiring for the July-September quarter, with a net employment outlook of 30%, six percentage points lower than the current quarter and the same period last year. While 48% of employers plan to hire more people, 18% expect a decrease in hiring or have no plans to hire. The most optimistic sectors are finance and real estate, healthcare and life sciences, and IT, while communication services and transport, logistics, and automotive are less optimistic.
Around one-third employees experience age-related discrimination at work: Study
The 'Ageism in the Workplace' study by talent company Randstad India revealed that 31 per cent of employees in India have experienced discriminations due to their age and such discriminations are mostly prevalent during recruitment process, especially in job advertisements of organisations.
31% of employees in India experienced ageism at work: Randstad
A study by Randstad India has revealed that 31% of Indian employees have experienced bias or discrimination due to their age at work. The study, which covered nearly 1,000 respondents, found that pharma, healthcare & life sciences, and business process outsourcing/IT-enabled services were the sectors where the highest proportions of respondents experienced ageism. Construction, infrastructure, and real estate followed closely, with 41% of respondents experiencing ageism.
Initiatives on track to increase women’s participation across levels, say 54% Indian employers – much above global average of 46%
Internal leadership development programmes, followed by flexible working policies, most effective in helping retain and secure diverse talent, finds ManpowerGroup Diversity Outlook Survey
- Go To Page 1
Chinese scientists develop cure for diabetes, insulin patient becomes medicine-free in just 3 months
Chinese scientists achieve diabetes cure through innovative cell therapy, detailed in Cell Discovery. Patient, treated in July 2021, no longer requires insulin after eleven weeks, and is now medication-free for 33 months. The breakthrough, praised by Timothy Kieffer, signifies a major advancement in diabetes treatment. This novel approach utilizes the body's regenerative abilities and could alleviate China's healthcare burden. Further studies are needed for validation.
Responsible Innovation, how a blueprint for collaborative action is advancing global healthcare
On the occasion of the Abu Dhabi Global Healthcare Week (ADGHW), Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre, discusses the UAE's prioritisation of healthcare in driving investments and partnerships focusing on advancing technology and attracting top talent and fostering collaboration with India reflecting shared challenges and opportunities in healthcare. Overall, collaboration with global partners and investment in manufacturing capabilities exemplify the UAE's commitment to healthcare excellence and innovation, while initiatives like Malaffi enhance data-driven services. Read on to discover how ADGHW aims to faciliate responsible innovation in healthcare, even as the UAE emphasises patient rights protection in an era of advancing AI and data usage.
Empowering healthcare innovations: Dr. Noura Khamis Al Ghaithi on ADGHW's role in global healthcare collaboration
H.E. Dr. Noura Khamis Al Ghaithi discusses ADGHW as a platform for global healthcare collaboration, focusing on innovations and partnerships with Indian healthcare providers. The event aims to develop precision health initiatives, strengthen life sciences research, attract medical tourism, and support a growing startup ecosystem.
10 Best Omega 3 Supplements in India for health
In India, several Omega-3 supplements stand out for their quality and efficacy. These supplements are rich in essential fatty acids like EPA and DHA, which play crucial roles in supporting heart health, brain function, and overall well-being. When choosing an Omega-3 supplement, it's essential to look for trusted brands that prioritize quality and transparency in sourcing and manufacturing processes. For best results, find the list of the best Omega 3 supplements.
Indegene IPO booked over 10x so far on Day 3. Check subscription, GMP and other details
Indegene IPO GMP: On the final day of the initial public offer (IPO), Indegene was booked a little over 10 times so far on Wednesday, the last day of the bidding process.
Indegene IPO booked over 4x so far on Day 2. Check subscription, GMP and other details
Indegene's IPO oversubscribed 4 times on the second day, led by non-institutional investors; QIB portion least subscribed.
Indegene IPO fully subscribed on Day 1. Check subscription, GMP and other details
On the first day of bidding, the initial public offering (IPO) of Indegene Ltd received a steady response, primarily fueled by strong interest from non-institutional investors (NII).
Indegene offers value to life sciences, needs price discovery
The Bengaluru-based company is rolling out a ₹1,842 crore initial public offering comprising a fresh issue of ₹760 crore and an offer of sale of ₹1,082 crore. The IPO represents 17% of the company's post-issue paid-up capital. Proceeds of the issue will be used to trim debt and for capex.
Anand Rathi initiates coverage on 6 hospital stocks with upside potential of up to 25%
Anand Rathi initiates coverage on 6 hospital stocks, recommending 'buy' for Max Healthcare, Rainbow Children’s Medicare, KIMS, and Jupiter Life-Line Hospitals, while suggesting 'hold' for Global Health (MEDANTA) and Narayana Hrudayalaya. They cite India's healthcare market potential, driven by demographic changes and non-communicable diseases, forecasting 15% CAGR to Rs 7.7 lakh crore by FY25.
HCG founder floats $20 million healthcare and life sciences fund
BS Ajaikumar launched the $20 million Inviga Healthcare Fund to support Indian early-stage healthcare companies, addressing funding and operational challenges. The fund recently invested $2 million in Mynvax for novel vaccines.
Warburg Pincus acquires Chennai's Appasamy Associates
PSN Appasamy's Appasamy Associates, a key player in Indian ophthalmic market, focuses on affordable equipment and cataract surgeries. Warburg Pincus's investment reinforces growth potential in the sector.
Dhananjay Singh takes over as Merck Life Science India MD
In his role as the managing director, Singh will be responsible for driving the life science strategy in India, ensuring governance and compliance alongside other leaders from Merck's businesses in India. He joined Sigma-Aldrich in 1997. Over the years he took on several leadership roles in commercial organisations before his appointment as head of science and lab solutions commercial for India, a position he held since 2022.
'Iron Man' tech in real life? China to develop fibers which can convert T-shirts into electronic devices
Chinese researchers are working on wearable smart 't-shirts' that will have all the next-gen features for users, bringing in a new kind of tech revolution.
GPT Healthcare debut exceeds expectations. Should you wait for more upside?
The shares of GPT Healthcare debuted with a 15% premium over the issue price on Thursday, which was slightly above expectations. Most analysts priced in a 9-10% premium listing.
GPT Healthcare shares list at 16% premium over IPO price
GPT Healthcare Share Price: GPT Healthcare's IPO debuted with a 16.2% premium. It raised Rs 525 crore for prepayment/repayment of borrowings. The company operates four multispecialty hospitals. Revenue grew at 53.87% CAGR. Three-month total income was Rs 97.63 crore, net profit was Rs 9.98 crore.
GPT Healthcare to debut tomorrow. Here's what GMP indicates ahead of listing
The shares of GPT Healthcare will debut on the exchanges on Thursday. Ahead of the listing, the company's shares are trading with a premium of Rs 17 in the unlisted market.
GPT Healthcare IPO allotment: Check status, listing date, GMP and other details
GPT Healthcare IPO received 8.5 times subscription. Share allotment to be finalized. Check status on BSE or registrar website. Shares trading with Rs 10 premium. Proceeds used for repayment. Competing with listed peers. JM Financial is the sole book running lead manager.
GPT Healthcare IPO fully subscribed on last day. Check GMP and other details
In the unlisted market, the company's shares are trading with a premium of Rs 10, marginally up from the previous week.
GPT Healthcare IPO: Check subscription on Day 1, GMP and other details
GPT Healthcare IPO is priced at Rs 177-186 per share for its Rs 525-crore IPO. Investors can make bids for 80 shares in one lot and its multiples thereafter.
GPT Healthcare IPO opens for subscription. Should you apply?
GPT Healthcare IPO: GPT Healthcare's IPO, valued at Rs 525 crore, opened for subscription. The company raised Rs 157 crore from anchor investors. Analysts advise subscribing for fair valuations, comprehensive services, and quality medical practices. The price band is Rs 177-186 per share.
GPT Healthcare IPO to open on Thursday. What GMP signals ahead of subscription?
GPT Healthcare has fixed a price band of Rs 177-186 per share for its Rs 525-crore IPO. The issue closes on February 26. Investors can make bids for 80 shares in one lot and multiples thereafter. The proceeds will be used for prepayment or repayment of all or a portion of certain outstanding borrowings availed by the company and for general corporate purposes.
Kolkata-based GPT Healthcare announces IPO dates. Check details
The IPO, with a face value of Rs 10, consists of a fresh issue of equity shares, aggregating to Rs 40 crore, and an offer for sale (OFS) of up to 2.6 crore equity shares by BanyanTree Growth Capital II, LLC, a Mauritius-based structured private equity.
Load More
